Targets › CDK1
2 programs from 1 company in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Mar 2027.
Plays a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle as well as mitotic onset; promotes G2-M transition via association with multiple interphase cyclins. Phosphorylates PARVA/actopaxin, APC, AMPH, APC, ASB7, BARD1, Bcl-xL/BCL2L1, BRCA2, CALD1, CASP8, CDC7, CDC20, CDC25A, CDC25C, CC2D1A, CENPA, CSNK2 proteins/CKII, FZR1/CDH1, CDK7, CEBPB, CHAMP1, DMD/dystrophin, EEF1…. (UniProt, P06493)
Open in Phaseline: the race on CDK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Dinaciclib Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 5 inhibitor | CDK1, CDK2, CDK5, CDK9 | Phase 2 | Acral Lentiginous Melanoma; Advanced Malignant Solid Neoplasm | Mar 2027 |
| National Cancer Institute (NCI) | Zotiraciclib Cyclin-dependent kinase 1 inhibitor; Cyclin-dependent kinase 2 inhibitor; Cyclin-dependent kinase 7 inhibitor | CDK1, CDK2, CDK7, CDK9, FLT3 | Phase 1 | Brain Tumor | Aug 2028 |
Brain Tumor (1) Acral Lentiginous Melanoma (1) Advanced Malignant Solid Neoplasm (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.